These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35076333)

  • 1. Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression.
    Roy T; An JB; Doucette K; Chappell AM; Vesole DH
    Leuk Lymphoma; 2022 Mar; 63(3):759-761. PubMed ID: 35076333
    [No Abstract]   [Full Text] [Related]  

  • 2. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
    Jelinek T; Mihalyova J; Kascak M; Duras J; Popkova T; Benkova K; Richterova P; Plonkova H; Zuchnicka J; Broskevicova L; Huvarova L; Cerna L; Growkova K; Simicek M; Havel M; Gumulec J; Navratil M; Koristek Z; Paiva B; Hajek R
    Am J Hematol; 2019 Jan; 94(1):E35-E37. PubMed ID: 30370955
    [No Abstract]   [Full Text] [Related]  

  • 3. Secondary plasma cell leukaemia treated with single agent venetoclax.
    Glavey SV; Flanagan L; Bleach R; Kelly C; Quinn J; Ní Chonghaile T; Murphy P
    Br J Haematol; 2020 Aug; 190(4):e242-e245. PubMed ID: 32525557
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute myeloid leukemia-driven IL-3-dependent upregulation of BCL2 in non-malignant hematopoietic stem and progenitor cells increases venetoclax-induced cytopenias.
    Fowler-Shorten DJ; Maynard RS; Hampton K; Altera A; Markham M; Ehikioya M; Wojtowicz EE; Bowles KM; Rushworth SA; Hellmich C
    Haematologica; 2024 May; 109(5):1576-1581. PubMed ID: 38186347
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14).
    Gonsalves WI; Buadi FK; Kumar SK
    Eur J Haematol; 2018 Feb; 100(2):215-217. PubMed ID: 29064593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How do we manage t(11;14) plasma cell disorders with venetoclax?
    Chakraborty R; Bhutani D; Lentzsch S
    Br J Haematol; 2022 Oct; 199(1):31-39. PubMed ID: 35594184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma cell leukaemia with t(11;14) not responsive to venetoclax.
    Abu Zaanona MI; Patel P
    BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33495184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for Venetoclax in Myelodysplastic Syndromes.
    Garcia JS
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):441-448. PubMed ID: 32089221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax resistance and acquired
    Tausch E; Close W; Dolnik A; Bloehdorn J; Chyla B; Bullinger L; Döhner H; Mertens D; Stilgenbauer S
    Haematologica; 2019 Sep; 104(9):e434-e437. PubMed ID: 31004028
    [No Abstract]   [Full Text] [Related]  

  • 10. Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.
    Leverson JD; Sampath D; Souers AJ; Rosenberg SH; Fairbrother WJ; Amiot M; Konopleva M; Letai A
    Cancer Discov; 2017 Dec; 7(12):1376-1393. PubMed ID: 29146569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.
    Huemer F; Melchardt T; Jansko B; Wahida A; Jilg S; Jost PJ; Klieser E; Steiger K; Magnes T; Pleyer L; Greil-Ressler S; Rass C; Greil R; Egle A
    Eur J Haematol; 2019 May; 102(5):437-441. PubMed ID: 30725494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity "graft-versus-leukemia effects".
    Nagasaki J; Nishimoto M; Koh H; Okamura H; Nakamae M; Sakatoku K; Ido K; Kuno M; Makuuchi Y; Takakuwa T; Nakashima Y; Hino M; Nakamae H
    Blood Cancer J; 2024 May; 14(1):79. PubMed ID: 38744860
    [No Abstract]   [Full Text] [Related]  

  • 13. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.
    Blombery P; Thompson ER; Nguyen T; Birkinshaw RW; Gong JN; Chen X; McBean M; Thijssen R; Conway T; Anderson MA; Seymour JF; Westerman DA; Czabotar PE; Huang DCS; Roberts AW
    Blood; 2020 Mar; 135(10):773-777. PubMed ID: 31951646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
    Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
    Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
    [No Abstract]   [Full Text] [Related]  

  • 16. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
    Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
    Boidol B; Kornauth C; van der Kouwe E; Prutsch N; Kazianka L; Gültekin S; Hoermann G; Mayerhoefer ME; Hopfinger G; Hauswirth A; Panny M; Aretin MB; Hilgarth B; Sperr WR; Valent P; Simonitsch-Klupp I; Moriggl R; Merkel O; Kenner L; Jäger U; Kubicek S; Staber PB
    Blood; 2017 Dec; 130(23):2499-2503. PubMed ID: 28972014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical analysis of the combination regimen with Bcl-2 inhibitor venetoclax in the treatment of 30 cases of acute myeloid leukemia with IDH1/2 mutation].
    Wang X; Bao XB; Zhang J; Song BQ; Li MY; Xie JD; Shen HJ; Wu DP; Qiu HY
    Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):691-694. PubMed ID: 36709157
    [No Abstract]   [Full Text] [Related]  

  • 19. Is venetoclax the new backbone of acute myeloid leukaemia therapy?
    Jain P; Mims AS
    Lancet Haematol; 2021 Aug; 8(8):e536-e537. PubMed ID: 34329570
    [No Abstract]   [Full Text] [Related]  

  • 20. SOHO State of the Art Updates and Next Questions | Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions.
    Bennett R; Thompson E; Tam C
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):795-804. PubMed ID: 35970756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.